Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS

Summary

This study will assess the efficacy and safety of PTC857 treatment in participants diagnosed with ALS.

Timeline

Start

2022-05-15

Primary completion

2024-09-26

Completion

2025-01-30

Outcome

Missed primary endpoint

Stopped: “Company decision”

registry analysis (other test); Utreloxastat vs Placebo; p = 0.516; Treatment Difference 6.86 (95% CI -13.86 to 27.59); ANCOVA NCT05349721 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	UTRELOXASTAT	Small molecule	—	Oral

Indications